SGLT2 inhibitors in heart failure with preserved ejection fraction

Keyphrases

• Heart Failure with Preserved Ejection Fraction (HFpEF) 100%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 100%
• Heart Failure 50%
• Patient Demographics 25%
• Clinical Trials 25%
• Therapeutic Potential 25%
• Hospitalization 25%
• Clinical Syndromes 25%
• Sodium 25%
• Functional Impairment 25%
• Left Ventricular Ejection Fraction 25%
• Patients with Heart Failure 25%
• Structural Impairment 25%

Medicine and Dentistry

• Sodium Glucose Cotransporter 2 Inhibitor 100%
• Heart Failure with Preserved Ejection Fraction 100%
• Congestive Heart Failure 50%
• Clinical Trial 25%
• Patient Population 25%
• Prevalence 25%
• Clinical Syndrome 25%
• Heart Left Ventricle Ejection Fraction 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Sodium Glucose Cotransporter 2 Inhibitor 100%
• Heart Failure with Preserved Ejection Fraction 100%
• Congestive Heart Failure 50%
• Clinical Trial 25%
• Syndrome 25%
• Prevalence 25%